Patients must be able to swallow capsules
Patients must be able to swallow whole capsules
Patients must be able to swallow intact capsules
Patients must be able to swallow intact capsules
Able to swallow capsules
Inability to swallow capsules or known gastrointestinal malabsorption
Able to swallow ribociclib capsules
Patient must be able to swallow capsules
Able to swallow capsules
Able to swallow capsules
The subject is unable to swallow capsules.
Inability to swallow capsules
Inability to swallow gelatin capsules, or any medical condition that interferes with normal gastrointestinal absorption
Inability to swallow capsules, since capsules cannot be crushed or broken
Patients must be able to swallow capsules
Patient must be able to swallow capsules
Are able to swallow capsules
Unable to swallow capsules or disease significantly affecting gastrointestinal function
Patients must be able to swallow intact capsules
Patients must be able to swallow capsules
Are able to swallow capsules.
Able to swallow intact capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
The subject is unable to swallow capsules
Ability to swallow capsules unless enrolled in Part E
Part E: Any patient unable to swallow capsules who otherwise meet all other eligibility criteria for Part A (expansion) B, C or D
Able to swallow capsules
Patients must be able to swallow AZD capsules
Ability to swallow and retain capsules.
Ability to swallow capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
PART  GROUP  INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
PART  GROUP A INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
PART  GROUP  INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily; although, patients unable to swallow capsules will be allowed to participate in this study, by following the specific instructions on making a slurry of the medication
Patients must be able to swallow intact capsules whole
Patient must be able to swallow capsules
Unable to swallow capsules
Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsules
Patient must be able to swallow capsules
Able to swallow capsules, with no surgical or anatomic condition that will preclude the patient from swallowing and absorbing oral medications
Participants must be able to swallow capsules
Able to swallow capsules whole (pomalidomide capsules cannot be crushed, dissolved or broken)
Patients must be able to swallow whole capsules
Patients must be able to swallow capsules
Patient must be able to swallow capsules
Patients must be able to swallow capsules
Must be able to swallow ribociclib capsules
Patients must be able to swallow capsules whole
PHASE II: Patients must be able to swallow capsules whole
Known inability to swallow capsules
Patients must be able to swallow whole capsules
Patients must be able to swallow capsules whole
Part C: Patients must be able to swallow intact capsules
Patients unable to swallow whole capsules
Able to swallow whole capsules
Patients must be able to take oral medications; patients must be able to swallow capsules whole without crushing or altering them in any way
are able to swallow capsules
Patients must be able to swallow whole capsules
Inability to swallow capsules.
Unable to swallow capsules or disease significantly affecting gastrointestinal function
Patients must be able to swallow whole capsules
Subject is able to swallow capsules
Unable to swallow capsules or disease significantly affecting gastrointestinal function
Are able to swallow capsules
Unable to swallow capsules
Patients must be able to swallow capsules
Inability to swallow capsules
Patients must be able to swallow whole capsules
Inability to swallow capsules.
Able to swallow capsules
Patients who cannot swallow capsules
Patients must be able to swallow intact capsules
Inability to swallow capsules or known gastrointestinal malabsorption
Ability to swallow oral capsules
Are able to swallow capsules
Inability to swallow the HKI- capsules
Able to swallow capsules
Able to swallow capsules
Inability to swallow capsules
Patients must be able to swallow whole capsules; capsules must not be crushed or chewed; capsules must not be opened
Known inability to swallow up to five ceritinib (LDK) capsules daily
Inability to swallow oral capsules
Able to swallow capsules and maintain adequate hydration
Patients will be excluded if they are unable to swallow capsules whole.
Must be able to swallow whole capsules
Patients must be able to swallow capsules
Patients must be able to swallow whole capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
Able to swallow whole capsules
Patients must be able to swallow capsules
Patients must be able to swallow either intact capsules or mini-tabs without chewing
Patient must have the ability to swallow multiple capsules
Able to swallow capsules
Able to swallow oral capsules without difficulty.
Able to swallow capsules
Patient must be able to swallow capsules (phase III only)
Patients must be able to swallow whole capsules
Unable to swallow capsules or disease significantly affecting gastrointestinal function
